Infinity Pharmaceuticals
Infinity Pharmaceuticals
INFIQ
OTC
0.00
USD
0.00%
About
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma).
Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC).
MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 8.5K |
| Three Month Average Volume | 254.1K |
| High Low | |
| Fifty-Two Week High | 0.1 USD |
| Fifty-Two Week Low | 0 USD |
| Fifty-Two Week High Date | 06 Sep 2023 |
| Fifty-Two Week Low Date | 28 Aug 2024 |
| Price and Volume | |
| Current Price | 0 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -5.34% |
| Thirteen Week Relative Price Change | -6.57% |
| Twenty-Six Week Relative Price Change | -9.05% |
| Fifty-Two Week Relative Price Change | -100.00% |
| Year-to-Date Relative Price Change | -99.97% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 0.00% |
| Twenty-Six Week Price Change | 0.00% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -100.00% |
| Year-to-Date Price Change | -99.96% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.21307 USD |
| Book Value Per Share (Most Recent Quarter) | -0.41214 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.21307 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.41214 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.46494 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.02905 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.0287 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.49714 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.45747 USD |
| Normalized (Last Fiscal Year) | -0.49714 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.49714 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.45747 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.49714 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.45747 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.4285 USD |
| Cash Per Share (Most Recent Quarter) | 0.19552 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.49201 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.45268 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.4344 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -534 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,514 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,593.93% |
| Pretax Margin (Last Fiscal Year) | -1,711.11% |
| Pretax Margin (5 Year) | -600.95% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 39.72% |
| Gross Margin (Trailing Twelve Months) | 39.70% |
| Gross Margin (5 Year) | 64.62% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,729.43% |
| Operating Margin (Trailing Twelve Months) | -1,636.67% |
| Operating Margin (5 Year) | -593.07% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,711.11% |
| Net Profit Margin (Trailing Twelve Months) | -1,593.93% |
| Net Profit Margin (5 Year) | -600.77% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -15.01% |
| Revenue Growth (3 Year) | -15.45% |
| Revenue Change (Trailing Twelve Months) | 15.88% |
| Revenue Per Share Growth | -24.53% |
| Revenue Growth (5 Year) | -5.26% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -16.94% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 17.61% |
| EPS Change (Trailing Twelve Months) | 12.93% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -17,746,000 |
| Net Debt (Last Fiscal Year) | -38,313,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 2 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 2 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -42,448,000 |
| Free Cash Flow (Trailing Twelve Months) | -38,884,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -69.91% |
| Return on Assets (Trailing Twelve Months) | -98.56% |
| Return on Assets (5 Year) | -66.33% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -3,521.35% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -257.75% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -88.73% |
| Return on Investment (Trailing Twelve Months) | -144.47% |
| Return on Investment (5 Year) | -82.03% |